237 related articles for article (PubMed ID: 22798675)
21. Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T cells for melanoma immunotherapy in human MHC class I-transgenic mice.
Bullock TN; Mullins DW; Colella TA; Engelhard VH
J Immunol; 2001 Nov; 167(10):5824-31. PubMed ID: 11698456
[TBL] [Abstract][Full Text] [Related]
22. Avidity characterization of genetically engineered T-cells with novel and established approaches.
Hillerdal V; Boura VF; Björkelund H; Andersson K; Essand M
BMC Immunol; 2016 Jul; 17(1):23. PubMed ID: 27411667
[TBL] [Abstract][Full Text] [Related]
23. A rare population of tumor antigen-specific CD4
Matsuzaki J; Tsuji T; Chodon T; Ryan C; Koya RC; Odunsi K
J Immunother Cancer; 2019 Jan; 7(1):7. PubMed ID: 30626427
[TBL] [Abstract][Full Text] [Related]
24. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma.
Van den Hove LE; Van Gool SW; Van Poppel H; Baert L; Coorevits L; Van Damme B; Ceuppens JL
Clin Exp Immunol; 1997 Sep; 109(3):501-9. PubMed ID: 9328129
[TBL] [Abstract][Full Text] [Related]
25. Vaccines targeting tumor blood vessel antigens promote CD8(+) T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice.
Zhao X; Bose A; Komita H; Taylor JL; Chi N; Lowe DB; Okada H; Cao Y; Mukhopadhyay D; Cohen PA; Storkus WJ
J Immunol; 2012 Feb; 188(4):1782-8. PubMed ID: 22246626
[TBL] [Abstract][Full Text] [Related]
26. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma.
Kawakami Y; Dang N; Wang X; Tupesis J; Robbins PF; Wang RF; Wunderlich JR; Yannelli JR; Rosenberg SA
J Immunother; 2000 Jan; 23(1):17-27. PubMed ID: 10687134
[TBL] [Abstract][Full Text] [Related]
27. Differential in situ expansion and gene expression of CD4+ and CD8+ tumor-infiltrating lymphocytes following adoptive immunotherapy in a murine tumor model system.
Evans R; Duffy TM; Kamdar SJ
Eur J Immunol; 1991 Aug; 21(8):1815-9. PubMed ID: 1907916
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ.
Moran AE; Polesso F; Weinberg AD
J Immunol; 2016 Sep; 197(6):2509-21. PubMed ID: 27503208
[TBL] [Abstract][Full Text] [Related]
29. Characterization of defective CD4-CD8- T cells in murine tumors generated independent of antigen specificity.
Prins RM; Incardona F; Lau R; Lee P; Claus S; Zhang W; Black KL; Wheeler CJ
J Immunol; 2004 Feb; 172(3):1602-11. PubMed ID: 14734741
[TBL] [Abstract][Full Text] [Related]
30. Isolation and Characterization of an HLA-DRB1*04-Restricted HPV16-E7 T Cell Receptor for Cancer Immunotherapy.
Mercier-Letondal P; Marton C; Deschamps M; Ferrand C; Vauchy C; Chenut C; Baguet A; Adotévi O; Borg C; Galaine J; Godet Y
Hum Gene Ther; 2018 Oct; 29(10):1202-1212. PubMed ID: 30136612
[TBL] [Abstract][Full Text] [Related]
31. IL6 Induces an IL22
St Paul M; Saibil SD; Lien SC; Han S; Sayad A; Mulder DT; Garcia-Batres CR; Elford AR; Israni-Winger K; Robert-Tissot C; Zon M; Katz SR; Shaw PA; Clarke BA; Bernardini MQ; Nguyen LT; Haibe-Kains B; Pugh TJ; Ohashi PS
Cancer Immunol Res; 2020 Mar; 8(3):321-333. PubMed ID: 31964625
[TBL] [Abstract][Full Text] [Related]
32. Altered differentiation, diminished pathogenicity, and regulatory activity of myelin-specific T cells expressing an enhanced affinity TCR.
Alli R; Nguyen P; Geiger TL
J Immunol; 2011 Dec; 187(11):5521-31. PubMed ID: 22025553
[TBL] [Abstract][Full Text] [Related]
33. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
Inoue M; Plautz GE; Shu S
Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987
[TBL] [Abstract][Full Text] [Related]
34. Characterization of MHC class-I restricted TCRalphabeta+ CD4- CD8- double negative T cells recognizing the gp100 antigen from a melanoma patient after gp100 vaccination.
Voelkl S; Moore TV; Rehli M; Nishimura MI; Mackensen A; Fischer K
Cancer Immunol Immunother; 2009 May; 58(5):709-18. PubMed ID: 18836718
[TBL] [Abstract][Full Text] [Related]
35. Human melanoma immunotherapy using tumor antigen-specific T cells generated in humanized mice.
Hu Z; Xia J; Fan W; Wargo J; Yang YG
Oncotarget; 2016 Feb; 7(6):6448-59. PubMed ID: 26824989
[TBL] [Abstract][Full Text] [Related]
36. Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen.
Denkberg G; Lev A; Eisenbach L; Benhar I; Reiter Y
J Immunol; 2003 Sep; 171(5):2197-207. PubMed ID: 12928363
[TBL] [Abstract][Full Text] [Related]
37. Human CD8 transgene regulation of HLA recognition by murine T cells.
LaFace DM; Vestberg M; Yang Y; Srivastava R; DiSanto J; Flomenberg N; Brown S; Sherman LA; Peterson PA
J Exp Med; 1995 Nov; 182(5):1315-25. PubMed ID: 7595202
[TBL] [Abstract][Full Text] [Related]
38. Positive selection of T cells: rescue from programmed cell death and differentiation require continual engagement of the T cell receptor.
Kisielow P; Miazek A
J Exp Med; 1995 Jun; 181(6):1975-84. PubMed ID: 7759993
[TBL] [Abstract][Full Text] [Related]
39. T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines.
Shilyansky J; Nishimura MI; Yannelli JR; Kawakami Y; Jacknin LS; Charmley P; Rosenberg SA
Proc Natl Acad Sci U S A; 1994 Mar; 91(7):2829-33. PubMed ID: 7511820
[TBL] [Abstract][Full Text] [Related]
40. CD4+ Th1 cells promote CD8+ Tc1 cell survival, memory response, tumor localization and therapy by targeted delivery of interleukin 2 via acquired pMHC I complexes.
Huang H; Hao S; Li F; Ye Z; Yang J; Xiang J
Immunology; 2007 Feb; 120(2):148-59. PubMed ID: 17274112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]